A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 3, 2008, Pages 395-405

  Bornmann, C ^a   Graeser, R ^b   Esser, N ^b   Ziroli, V ^c   Jantscheff, P ^c   Keck, T ^a   Unger, C ^c   Hopt, U T ^a   Adam, U ^a   Schaechtele, C ^b   Massing, U ^c   Von Dobschuetz, E ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b PROQINASE GMBH   (Germany)

^c TUMOR BIOLOGY CENTER   (Germany)

Author keywords

Bioluminescence; Gemcitabine; Liposomes; Orthotopic; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; GEMLIP; LIPOSOME; LUCIFERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CELL GROWTH; CONTROLLED STUDY; DRUG FORMULATION; ENZYME ACTIVITY; FEMALE; LIVER METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DEOXYCYTIDINE; DRUG CARRIERS; DRUG COMPOUNDING; EVANS BLUE; LIPOSOMES; LUCIFERASES; LUMINESCENCE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PERMEABILITY;

EID: 37249047522     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0482-z     Document Type: Article

References (33)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ (2004) CA Cancer J Clin 54(1):8-29
2. Noble S, Goa KL (1997) Drugs 54(3):447-472
3. Axelson J, Lindell M, Horlin K, Ohlsson B (2005) Pancreatology 5(2-3):251-258
4. Zagon IS, Jaglowski JR, Verderame MF, Smith JP, Leure-Dupree AE, McLaughlin PJ (2005) Cancer Chemother Pharmacol 56(5):510-520
5. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN et al (1991) J Clin Oncol 9(3):491-498
6. Wang LR, Huang MZ, Xu N, Shentu JZ, Liu J, Cai J (2005) J Zhejiang Univ Sci B 6(5):446-450
7. Reid JM, Qu W, Safgren SL, Ames MM, Krailo MD, Seibel NL, Kuttesch J, Holcenberg J (2004) J Clin Oncol 22(12):2445-2451
8. Moog R, Burger AM, Brandl M, Schuler J, Schubert R, Unger C, Fiebig HH, Massing U (2002) Cancer Chemother Pharmacol 49(5):356-366
9. Shipley LA, Brown TJ, Cornpropst JD, Hamilton M, Daniels WD, Culp HW (1992) Drug Metab Dispos 20(6):849-855
10. van Borssum Waalkes M, Kuipers F, Havinga R, Scherphof GL (1993) Biochim Biophys Acta 1176(1-2):43-50
11. van Borssum Waalkes M, van Galen M, Morselt H, Sternberg B, Scherphof GL (1993) Biochim Biophys Acta 1148(1):161-172
12. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK (1995) Cancer Res 55(17):3752-3756
13. Massing U (1997) Int J Clin Pharmacol Ther 35(2):87-90
14. Massing U, Fuxius S (2000) Drug Resist Updat 3(3):171-177
15. Brandl M, Massing U (2003) Vesicular phospholipid gels. In: New RW, Torchillin V (eds) Liposomes practical approaches. IRL-Press at Oxford University Press, Oxford
16. Schueler J (1998) Entwicklung und Charakterisierung humaner Tumormodelle durch orthotope Implantation. In: Inst. für Veterinärpathologie, Freie Universität, Berlin
17. Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, Kloppel G (2003) Virchows Arch 442(5):444-452
18. Bold RJ, Chandra J, McConkey DJ (1999) Ann Surg Oncol 6(3):279-285
19. Katz MH, Bouvet M, Takimoto S, Spivack D, Moossa AR, Hoffman RM (2003) Cancer Res 63(17):5521-5525
20. Hotz HG, Reber HA, Hotz B, Yu T, Foitzik T, Buhr HJ, Cortina G, Hines OJ (2003) Pancreas 26(4):e89-e98
21. Tomioka D, Maehara N, Kuba K, Mizumoto K, Tanaka M, Matsumoto K, Nakamura T (2001) Cancer Res 61(20):7518-7524
22. Tsutsumi S, Yanagawa T, Shimura T, Kuwano H, Raz A (2004) Clin Cancer Res 10(22):7775-7784
23. Bouvet M, Yang M, Nardin S, Wang X, Jiang P, Baranov E, Moossa AR, Hoffman RM (2000) Clin Exp Metastasis 18(3):213-218
24. Shah K, Weissleder R (2005) NeuroRx 2(2):215-225
25. Tardi C (1999) Vesikuläre Phospholipidgele: in vitro Charakterisierung, Autoklavierbarkeit, Anwendung als Depotarzneiform. In. Dept. Pharmaceutical Technology, Albert-Ludwigs-University of Freiburg, Freiburg
26. Gossen M, Bujard H (1992) Proc Natl Acad Sci USA 89(12):5547-5551
27. Workman P, Balmain A, Hickman JA, McNally NJ, Rohas AM, Mitchison NA, Pierrepoint CG, Raymond R, Rowlatt C, Stephens TC et al (1988) Lab Anim 22(3):195-201
28. Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M (2004) Clin Cancer Res 10(9):2936-2943
29. Braakhuis BJ, van Dongen GA, Vermorken JB, Snow GB (1991) Cancer Res 51(1):211-214
30. Sener SF, Fremgen A, Menck HR, Winchester DP (1999) J Am Coll Surg 189(1):1-7
31. Eibl G, Reber HA (2005) Pancreas 31(3):258-262
32. Keller R (1985) Invasion Metastasis 5(5):295-308
33. Nagami H, Nakano K, Ichihara H, Matsumoto Y, Ueoka R (2006) Bioorg Med Chem Lett 16(4):782-785